By: Zach Hartman From: seekingalpha.com Summary Puma Biotechnology is known almost exclusively as a breast cancer company. New basket study results may portend a move outside of there, but you have to think outside the box. How relevant are HER2 mutations, though? Puma Biotechnology (PBYI) has made its entire game up on the back of one drug, a “pan-HER” inhibitor …
Larotrectinib: Targeting DNA in cancer therapy
Source: Children’s Hospital Los Angeles While other toddlers her age were fighting naptime, two-year-old Michelle was battling an aggressive, life-threatening cancer. Doctors at Children’s Hospital Los Angeles saved her life in an epic battle, wielding what is being hailed as a “magic bullet” in the fight against certain cancers. CHLA’s Leo Mascarenhas, MD, MS, saw promise in larotrectinib when he …
New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors
From: cancerresearch.org 2,250 clinical trials are evaluating PD-1/L1 immune checkpoint inhibitors, an increase of 748 trials over the past year 1,716 trials are assessing regimens that combine PD-1/L1 immune checkpoints with other cancer therapies 240 drug targets are being evaluated in the current landscape, 75 more targets compared to a year ago Over 380,000 patient volunteers are required to fill …
NCRI 2018: Using liquid biopsies to understand cancer treatment
By: Francis Newman From: icr.ac.uk Testing for cancer cells and DNA in the bloodstream is showing huge promise as a way of monitoring cancers and how they are responding to treatment. At the 2018 NCRI conference in Glasgow, ICR researchers spoke about how these so-called liquid biopsies can guide clinical decisions for cancer patients. A liquid biopsy is a new …
The Holidays Are a Perfect Time to Discuss Your Family Medical History
View PostNew Clinical Research on Chimeric Antigen Receptor (CAR) T-Cell Therapy Presented at 60th American Society of Hematology Annual Meeting
Source: Yadira Galindo, Health Journalist The 60th American Society of Hematology (ASH) Annual Meeting, the largest international conference and exhibition in the field of hematology, is currently taking place at the San Diego Convention Center. Dr. Peihua Lu, the Medical Executive President of the Hebei Yanda Lu Daopei Hospital, and Dr. Xian Zhang from the same institution were invited by …
The future of fighting cancer: Zapping tumors in less than a second
Source: DOE/SLAC National Accelerator Laboratory From: sciencedaily.com New accelerator-based technology being developed by the Department of Energy’s SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under a second. Built into future compact medical devices, technology developed for high-energy physics could also help make radiation …
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
Source: QIAGEN From: apnews.com Nov 30, 2018–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of cancer-focused genetic testing services, will ensure Day-One patient access to …
End-of-life symptoms of metastatic breast cancer
By: Jennifer Berry From: medicalnewstoday.com Metastatic breast cancer occurs when the cancer spreads from the breast to another part of the body. Symptoms and treatment for this stage of breast cancer are different to those of the earlier stages. Doctors may also refer to metastatic breast cancer as advanced breast cancer or stage 4 breast cancer. Many people live for …
Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019
Tocagen Inc. (TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of the National Cancer Institute’s (NCI) National Clinical Trial Network (NCTN), today announced that the NCI Cancer Therapy and Evaluation Program (CTEP) Brain Malignancies Steering Committee has approved a concept to develop a clinical trial utilizing the investigational therapeutic regimen Toca 511 (vocimagene amiretrorepvec) & …